ASCO Annual Meeting Abstracts

Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study

British Journal of Haematology

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients

Blood

Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up

Journal of Clinical Oncology

Coverage and cost-of-care links: Addressing financial toxicity among patients with hematologic cancer and their caregivers

British Journal of Haematology

FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?

Clinical Lymphoma, Myeloma, & Leukemia

SOHO state of the art updates and next questions--New targetable pathways in chronic lymphocytic leukemia

Cancers (Basel)

The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: Future perspectives

New England Journal of Medicine

Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia

Lancet

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label single-arm, phase 1-2 study

ASCO 2023 Abstracts

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (ALLIANCE)